Valeda Light Delivery System Receives 2019 Medical Design Excellence Award

Source: LumiThera

LumiThera and Product Creation Studio announced that LumiThera’s Valeda Light Delivery System has won a silver award in the 21st Annual Medical Design Excellence Awards competition. The 2019 winners were announced at the MDEA Ceremony on Tuesday, June 11, 2019 in conjunction with the MD&M East event in New York, New York.

LumiThera is a leader in the use of photobiomodulation for the treatment of acute and chronic ocular diseases and disorders. Product Creation Studio worked with LumiThera from product concept through transfer to manufacturing to design and engineer a medical device that would accurately, safely, and effectively treat patients suffering from dry AMD. The resulting Valeda Light Delivery System is currently the only approved treatment using Photobiomodulation for dry AMD in the European Union.

The MDEA recognizes significant achievements in medical product design and engineering that improve the quality of healthcare delivery and accessibility.

“This award recognizes the efforts of the LumiThera and the Product Creation teams who have worked diligently to deliver a life changing treatment for those suffering from dry AMD,” Clark Tedford, PhD, CEO and President, said in a company news release. “We are pleased to bring the Valeda Light Delivery System to the ophthalmic market and offer dry AMD patients a treatment for this debilitating disease.”

“Product Creation Studio’s collaboration with LumiThera embodies what our organization is about: empowering innovators with the right design and development services at the right time to deliver products with impact,” said Scott Thielman, Chief Technology officer of Product Creation Studio. “The Valeda Light Delivery System is a breakthrough product that makes a meaningful difference for patients and their families. It has been an honor to support the LumiThera team with comprehensive engineering and design services from the company’s early days through production.”


Related Content